$6.1 B

ALLO Mkt cap, 27-May-2020
Allogene Therapeutics Net income (Q1, 2020)-54.5 M
Allogene Therapeutics EBIT (Q1, 2020)-57.7 M
Allogene Therapeutics Cash, 31-Mar-2020135.9 M
Allogene Therapeutics EV6.1 B

Allogene Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

R&D expense

151.9m144.5m

General and administrative expense

2.0k41.0m57.5m

Operating expense total

2.0k192.8m202.0m

EBIT

(2.0k)(192.8m)(202.0m)

Interest expense

3.4m

Pre tax profit

(2.0k)(211.6m)(184.9m)

Income tax expense

(117.0k)(331.0k)

Net Income

(2.0k)(211.5m)(183.8m)

EPS

(7.3)(1.8)

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

R&D expense

122.5m10.9m23.4m31.8m40.0m42.0m

General and administrative expense

2.6m12.5m11.3m13.1m14.2m15.0m15.6m

Operating expense total

2.6m135.0m22.2m36.5m46.0m55.0m57.7m

EBIT

(2.6m)(135.0m)(22.2m)(36.5m)(46.0m)(55.0m)(57.7m)

Interest expense

3.4m

Pre tax profit

(2.6m)(134.9k)(43.5m)(31.6m)(41.4m)(50.7m)(54.5m)

Income tax expense

(50.0k)(159.0k)33.0k

Net Income

(2.6m)(134.9k)(43.5m)(30.5m)(40.5m)(51.0m)(54.5m)

Allogene Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

92.4m175.1m

Current Assets

468.0m544.6m

PP&E

8.6m56.4m

Total Assets

773.9m717.8m

Accounts Payable

12.3m9.3m

Current Liabilities

2.0k29.5m33.1m

Long-term debt

34.5m51.3m

Total Debt

34.5m51.3m

Total Liabilities

2.0k70.7m88.8m

Common Stock

5.0k121.0k124.0k

Additional Paid-in Capital

914.3m1.0b

Retained Earnings

(2.0k)(211.5m)(396.1m)

Total Equity

(2.0k)703.2m629.0m

Debt to Equity Ratio

0 x0.1 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

1.1 x1.1 x

Allogene Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(2.0k)(211.5m)(184.6m)

Depreciation and Amortization

1.5m5.0m

Accounts Payable

8.8m(985.0k)

Cash From Operating Activities

(44.7m)(137.3m)

Purchases of PP&E

(3.2m)(50.8m)

Cash From Investing Activities

(632.8m)164.1m

Cash From Financing Activities

771.2m59.0m

Net Change in Cash

93.7m85.7m

Income Taxes Paid

(117.0k)(331.0k)

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(2.6m)(137.5m)(181.0m)(31.6m)(72.8m)(123.6m)(54.5m)

Depreciation and Amortization

450.0k953.0k695.0k1.8m3.2m2.0m

Accounts Payable

1.3m3.1m(348.0k)1.3m(3.1m)(1.0m)

Cash From Operating Activities

5.0k(6.0m)(23.2m)(30.3m)(55.1m)(87.1m)(40.8m)

Purchases of PP&E

(536.0k)(1.9m)(10.4m)(18.3m)(36.7m)(12.3m)

Cash From Investing Activities

(2.6m)(319.4m)32.9m77.4m156.2m(15.0m)

Cash From Financing Activities

152.6m426.7m684.0k920.0k2.5m16.6m

Net Change in Cash

5.0k143.9m84.1m3.3m23.2m71.6m(39.2m)

Allogene Therapeutics Ratios

USDY, 2020

EV/EBIT

-105 x

EV/CFO

-148.4 x

Financial Leverage

1.1 x

Allogene Therapeutics Operating Metrics

Sep, 2018FY, 2018FY, 2019

Patients Included in Clinical Trials

18 21 21

Preclinical Phase Products

7 7 8

Phase I Trials Products

1 1 4

Office and Laboratory Space, square feet

89.54 k222.49 k200.94 k